Giulia Marvaso, Assistant Professor in the Department of Oncology and Hemato-Oncology at the University of Milan and Radiation Oncologist at IEO Milan, shared a post on X:
“Can liquid biopsy guide treatment in oligorecurrent Prostate Cancer?
In RADIOSA we explored if a mutational signature in cfDNA predicts outcomes:
– HR mutations (BRCA1/2, ATM, TP53, etc.) = ↓PFS
– 19 mo vs 35 mo without HRMLiquid biopsy may help identify pts needing > intense treatment.”
Giulia Marvaso Highlights Evolving Evidence on SBRT and MDT Strategies at ESTRO25
